Navigation Links
Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis
Date:5/31/2011

first-line chemotherapy in newly diagnosed multiple myeloma patients(1). Final results of the international Phase IV study, REACT (RAD001 Expanded Access Clinical Trial in RCC), evaluating Afinitor® (everolimus) tablets for the treatment of advanced renal cell carcinoma following any available vascular endothelial growth factor targeted therapy, will also be presented(1).

Notable data about Novartis treatments at ASCO include:

  • Gleevec – Two studies on Gleevec in KIT+ GIST, including a Phase III trial examining the benefit of extended adjuvant treatment for three years versus one year with Gleevec for patients following resection of their KIT+ GIST (ASCO abstract #LBA1; June 5, 1:45 - 2:00 PM CDT) and long-term follow up of the pivotal Phase II trial examining overall survival and progression-free rates in patients with metastatic and/or inoperable GIST treated for nearly 10 years with Gleevec (ASCO abstract #10016; June 4, 8:00 AM - 1:00 PM CDT).

  • INC424 – Data from two pivotal Phase III studies evaluating INC424 in patients with myelofibrosis after 48 weeks of treatment compared to best available therapy in the COMFORT-II trial (ASCO abstract #LBA6501; June 6, 9:45 - 10:00 AM CDT), and after 24 weeks of treatment compared to placebo in COMFORT-I (ASCO abstract #6500; June 6, 9:30 - 9:45 AM CDT).

  • Tasigna Mutation analysis from ENESTnd comparing Tasigna to Gleevec in patients with newly diagnosed Ph+ CML in chronic phase (ASCO abstract #6502; June 6, 10:00 - 10:15 AM CDT) and ENESTnd 24-month update (ASCO abstract #6511; June 3, 2:00 - 6:00 PM CDT).

  • Zometa Two new Myeloma IX analyses evaluate the impact of treatment initiation and duration, and baseline bone disease status, on the effect of Zometa versus clodronate on progression-free survival, overall survival and skeletal-related events when used with first-line chemotherapy in patients w
    '/>"/>

  • SOURCE Novartis Pharmaceuticals Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

    Related medicine technology :

    1. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
    2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
    3. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
    4. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
    5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
    6. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
    7. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
    8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
    9. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
    10. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
    11. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/30/2014)... Germany , July 30, 2014  invendo ... and computer-assisted ("robotic") colonoscopy system, today announced the appointment ... medical device executive, as a new member of its ... highly respected global visionary in the medical device industry. ... and Chief Executive Officer at Given Imaging Ltd. (NASDAQ/TASE: ...
    (Date:7/30/2014)... TARRYTOWN, N.Y. and PARIS ... REGN ) and Sanofi (EURONEXT: SAN and ... new Phase 3 ODYSSEY trials of alirocumab in people ... greater percent reduction from baseline in low-density lipoprotein cholesterol ... comparator.  Alirocumab is an investigational monoclonal antibody targeting PCSK9 ...
    (Date:7/30/2014)... VEGAS , July 30, 2014  DigiPath, Inc. ... that is expanding into the cannabis testing and education ... in its business and affairs not previously disclosed or, ... the recent unusual market action. "We have ... over the last three trading days," said Steve ...
    Breaking Medicine Technology:invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 2invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8DigiPath No New Corporate Developments 2
    (Date:7/31/2014)... Pass, OR (PRWEB) July 31, 2014 Sales ... 12-percent from 2013 to 2014, according to radio talk show ... has been experiencing rapid growth since 1990. The US economy ... Sharon Kleyne Hour Power of Water radio show, reported this ... Bragg Live Foods, a worldwide manufacturer of organic and natural ...
    (Date:7/31/2014)... According to new research report ... by Type (Tofu, Tofu-Based Product, Tempeh, TVP, Seitan, ... Trends & Forecasts to 2019", defines and segments ... and forecasting of the market value of sources, ... also identifies the driving and restraining factors for ...
    (Date:7/31/2014)... July 31, 2014 Care Communications, Inc., ... outsourcing firm, has received the Elite Award for “Recruitment, ... Resources, one of twelve elite awards presented as part ... to Work For” 2014 awards competition. This marks ... Elite Award in the competition. CARE has also been ...
    (Date:7/31/2014)... July 31, 2014 Daily Gossip reveals in ... help sufferers discover some breakthrough weight loss tips. , ... tips and recommendations are very simple to implement. Users don’t ... foods, with no need to start counting calories. , ... who in fact created a 12 weeks weight loss program ...
    (Date:7/31/2014)... 31, 2014 In its latest blog post, ... believes that having family close by during a stay in ... the process is successful, is looking at 10 tips to ... , “Addiction recovery is a lifelong process, and one that ... committed to without compromise,” commented Best Drug Rehabilitation’s CEO ...
    Breaking Medicine News(10 mins):Health News:Organic Food Industry Grew 12% in 2013-2014 Reports Sharon Kleyne Hour Power of Water Host 2Health News:Organic Food Industry Grew 12% in 2013-2014 Reports Sharon Kleyne Hour Power of Water Host 3Health News:Meat Substitutes Market Worth $4,622.4 Million by 2019 - New Report by MarketsandMarkets 2Health News:Meat Substitutes Market Worth $4,622.4 Million by 2019 - New Report by MarketsandMarkets 3Health News:Care Communications, Inc. Named an Elite Award Winner Among Top Chicago Employers 2Health News:New Best Drug Rehabilitation Blog Posts Looks at 10 Tips for Coping After Drug or Alcohol Rehab 2
    ... century, John Snow mapped cases of cholera in Soho, London, ... water pump. Now, in a twenty-first century equivalent, scientists funded ... the latest in gene sequencing technology and global positioning system ... trace its source. Typhoid fever is caused by two ...
    ... Updated guidelines from the American Academy of Pediatrics (AAP) ... (ADHD) in younger children and in adolescents. Emerging ... in children from ages 4 to 18 (the previous ... 6 to 12). The new guidelines describe the special ...
    ... , SATURDAY, Oct. 15 (HealthDay News) -- Head injuries are ... a new study finds. Researchers examined data on 52 ... at a pediatric trauma center between 2003 and 2011. The ... 10 and the most common cause of injury was hitting ...
    ... BOSTON - An in-hospital delay of appendicitis treatment ... likelihood of complications, including perforation and abscess formation; ... according an abstract presented Saturday, Oct. 15 at ... and Exhibition in Boston. In "Missed Opportunities ...
    ... 14 (HealthDay News) -- Flu activity levels in the United ... get a flu shot, the U.S. Centers for Disease Control ... for the 2011-2012 flu season, the federal agency also said ... the U.S. supply is projected to be at an all-time ...
    ... One in six people in the United States is affected ... multiple sclerosis, and more research is required to find new ... mark its 20th anniversary, the foundation has released a video ... ongoing research. "Brain disease is in the news every ...
    Cached Medicine News:Health News:Google Earth typhoid maps reveal secrets of disease outbreaks 2Health News:Google Earth typhoid maps reveal secrets of disease outbreaks 3Health News:AAP expands ages for diagnosis and treatment of ADHD in children 2Health News:Delayed pediatric appendicitis treatment linked to complications, and even death 2Health News:Get Your Flu Shot Now, CDC Urges 2Health News:Foundation Aims to Raise Awareness of Brain Diseases 2
    ... patient tracking and billing. ... complete Handheld application, a ... complete CPT™ and ICD-9-CM ... AMA. Designed for any ...
    ... ToolBox is an advanced medical ... Emergency, Pediatric Dosing and Critical ... is a logical complement to ... as the Daviss Drug Guide, ...
    ... the handheld version of ... drug interaction analyzer covering ... generic drugs. iFacts™ enables ... to accurate and reliable ...
    A handy, quick reference for physicians, nurses, and other health care providers treating cancer patients....
    Medicine Products: